Guggenheim Initiates Coverage on Celcuity (NASDAQ:CELC)

Equities researchers at Guggenheim started coverage on shares of Celcuity (NASDAQ:CELC) in a report issued on Friday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $169.00 price target on the stock. Guggenheim‘s price target indicates a potential upside of 153.03% from the company’s previous close.

Several other equities research analysts also recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Celcuity in a research report on Tuesday, September 1st. Zacks Research lowered shares of Celcuity from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 13th. HC Wainwright reaffirmed a “buy” rating and issued a $155.00 price objective on shares of Celcuity in a research report on Friday, August 14th. TD Cowen reaffirmed a “buy” rating and issued a $145.00 price objective on shares of Celcuity in a research report on Wednesday, October 21st. Finally, Wall Street Zen downgraded Celcuity from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Celcuity has an average rating of “Moderate Buy” and an average price target of $152.14.

Celcuity Stock Up 4.3%

NASDAQ:CELC opened at $66.79 on Friday. The firm has a market cap of $3.27 billion, a P/E ratio of -14.18 and a beta of 0.16. The company has a debt-to-equity ratio of 6.04, a quick ratio of 8.93 and a current ratio of 8.93. Celcuity has a fifty-two week low of $53.54 and a fifty-two week high of $151.02. The firm has a 50-day simple moving average of $75.11 and a two-hundred day simple moving average of $99.38.

Celcuity (NASDAQ:CELC) last issued its earnings results on Thursday, November 5th. The company reported ($1.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.51) by $0.30. Analysts predict that Celcuity will post -4.98 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Celcuity

Several hedge funds and other institutional investors have recently bought and sold shares of CELC. Hsbc Holdings PLC bought a new position in shares of Celcuity during the 4th quarter valued at $1,058,000. California State Teachers Retirement System boosted its stake in shares of Celcuity by 91.2% in the 1st quarter. California State Teachers Retirement System now owns 25,580 shares of the company’s stock worth $2,920,000 after buying an additional 12,201 shares during the last quarter. Bank of America Corp DE purchased a new position in shares of Celcuity in the 2nd quarter worth $153,928,000. E Fund Management Co. Ltd. purchased a new position in shares of Celcuity in the 2nd quarter worth $4,802,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Celcuity in the second quarter worth $2,927,000. Institutional investors own 63.33% of the company’s stock.

More Celcuity News

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Celcuity reported a third-quarter loss of $1.21 per share, narrower than analysts’ expected loss of $1.51. The earnings beat may support sentiment. MarketBeat earnings report
• Positive Sentiment: The Q3 earnings-call summary highlighted strong launch momentum for Revtorpic, a potential positive commercial catalyst. Q3 2026 earnings-call highlights
• Positive Sentiment: Guggenheim kept its Buy rating and lowered its price target only modestly, from $171 to $169; the report cited substantial upside relative to the referenced share price. TickerReport article
• Negative Sentiment: Celcuity’s Q3 adjusted loss widened, a counterpoint to the per-share earnings beat and a reminder that the company remains loss-making. Celcuity Q3 adjusted loss widens

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company developing functional diagnostic tests designed to help identify cancer treatments that may be most effective for individual patients. Its technology analyzes living tumor cells taken from patients to measure how signaling pathways respond to different therapies, with the goal of supporting more personalized treatment decisions.

The company’s CELsignia platform is designed to assess the activity of cancer-related signaling pathways in patient-derived cells.